Home The Word Brain	My Amedeo FAQ Privacy About
	C49 + CC Journal Club For more information, please refer to our special emails from April 13 and May 19.

Parkinson's Disease

Free Subscription Articles published in Neurology Retrieve available abstracts of 95 articles: HTML format

Single Articles

June 2025
1. WANG P, Chen X, Na M, Flores-Torres MH, et al
   Long-Term Consumption of Ultraprocessed Foods and Prodromal Features of Parkinson Disease.
   Neurology. 2025;104:e213562.
   PubMed     Abstract available
   
   
   
2. MARAKI MI, Scarmeas N
   Fast Food, Slow Damage: The Role of Ultraprocessed Foods in Parkinson Disease.
   Neurology. 2025;104:e213684.
   PubMed    
   
   
   
3. YOUNG CB, Cholerton B, Smith AM, Shahid-Besanti M, et al
   The Parkinson's Disease Composite of Executive Functioning: A Measure for Detecting Cognitive Decline in Clinical Trials.
   Neurology. 2025;104:e213648.
   PubMed    
   
   
   May 2025
4. CHEN CC, Chiu JY, Tan AH, Toh TS, et al
   Investigating Plasma Metabolomics and Gut Microbiota Changes Associated With Parkinson Disease: A Focus on Caffeine Metabolism.
   Neurology. 2025;104:e213592.
   PubMed     Abstract available
   
   
   
5. BENARROCH E
   What Are Current Concepts on the Functional Organization of the Globus Pallidus Externus and Its Potential Role in Parkinson Disease?
   Neurology. 2025;104:e213623.
   PubMed    
   
   
   
6. POSTUMA RB
   Having Second Thoughts About Parkinson Diagnosis.
   Neurology. 2025;104:e213594.
   PubMed    
   
   
   
7. RATY V, Kuusimaki T, Majuri J, Vahlberg T, et al
   Stability and Accuracy of a Diagnosis of Parkinson Disease Over 10 Years.
   Neurology. 2025;104:e213499.
   PubMed     Abstract available
   
   
   
8. GANGULY J, Banerjee S, Basu P, Mukherjee S, et al
   Teaching Video NeuroImage: String Hallucinations in Parkinson Disease.
   Neurology. 2025;104:e213611.
   PubMed     Abstract available
   
   
   April 2025
9. SANCHEZ E, Coughlan GT, Wilkinson T, Ramirez J, et al
   Association of Plasma Biomarkers With Longitudinal Atrophy and Microvascular Burden on MRI Across Neurodegenerative and Cerebrovascular Diseases.
   Neurology. 2025;104:e213438.
   PubMed     Abstract available
   
   
   March 2025
10. YOO HS, Lee YG, Sohn YH, Yun M, et al
    Association of Relative Brain Hyperperfusion Independent of Dopamine Depletion With Motor Dysfunction in Patients With Parkinson Disease.
    Neurology. 2025;104:e213392.
    PubMed    
    
    
    
11. COUGHLIN DG, Shifflett B, Farris CM, Ma Y, et al
    alpha-Synuclein Seed Amplification Assay Amplification Parameters and the Risk of Progression in Prodromal Parkinson Disease.
    Neurology. 2025;104:e210279.
    PubMed     Abstract available
    
    
    
12. PALERMO G, Francesconi A, Bellini G, Morganti R, et al
    Involvement of the Nigrostriatal Pathway in Patients With Idiopathic Normal Pressure Hydrocephalus and Parkinsonism.
    Neurology. 2025;104:e213352.
    PubMed     Abstract available
    
    
    
13. LE HERON C, Horne KL, Macaskill MR, Livingston L, et al
    Author Response: Cross-Sectional and Longitudinal Association of Clinical and Neurocognitive Factors With Apathy in Patients With Parkinson Disease.
    Neurology. 2025;104:e209958.
    PubMed    
    
    
    
14. ZHANG X, Zhang Y, Ding C, Yang J, et al
    Reader Response: Cross-Sectional and Longitudinal Association of Clinical and Neurocognitive Factors With Apathy in Patients With Parkinson Disease.
    Neurology. 2025;104:e209812.
    PubMed    
    
    
    
15. GANESH A, Galetta SL
    Editors' Note: Cross-Sectional and Longitudinal Association of Clinical and Neurocognitive Factors With Apathy in Patients With Parkinson Disease.
    Neurology. 2025;104:e213339.
    PubMed    
    
    
    February 2025
16. YI MY, Cheng S, Chandra AA, Farkas N, et al
    Teaching Video NeuroImage: Methamphetamine-Induced Basal Ganglia Toxicity Presenting as Parkinsonism.
    Neurology. 2025;104:e213365.
    PubMed    
    
    
    
17. ISONAKA R, Sullivan P, Goldstein DS
    Pathophysiological Significance of alpha-Synuclein in Sympathetic Nerves: In Vivo Observations.
    Neurology. 2025;104:e210215.
    PubMed     Abstract available
    
    
    January 2025
18. DE BARTOLO MI, Ojha A, Leodori G, Piervincenzi C, et al
    Association of Early fMRI Connectivity Alterations With Different Cognitive Phenotypes in Patients With Newly Diagnosed Parkinson Disease.
    Neurology. 2025;104:e210192.
    PubMed     Abstract available
    
    
    
19. KOCH MW, Kalia LV, Sarna JR, Wile D, et al
    Feasibility of Simon 2-Stage Futility Trials in Early Parkinson Disease: Analysis of the PRECEPT and DATATOP Trial Datasets.
    Neurology. 2025;104:e210079.
    PubMed     Abstract available
    
    
    
20. ZIEGLER A, Schmid M
    Efficient Study Designs for the Early-Stage Evaluation of Disease-Modifying Treatments in Parkinson Disease.
    Neurology. 2025;104:e210218.
    PubMed    
    
    
    December 2024
21. YOO HS, Lee YG, Sohn YH, Yun M, et al
    Association of Relative Brain Hyperperfusion Independent of Dopamine Depletion With Motor Dysfunction in Patients With Parkinson Disease.
    Neurology. 2024;103:e210077.
    PubMed     Abstract available
    
    
    
22. YOO HS, Kim HK, Na HK, Kang S, et al
    Association of Striatal Dopamine Depletion and Brain Metabolism Changes With Motor and Cognitive Deficits in Patients With Parkinson Disease.
    Neurology. 2024;103:e210105.
    PubMed     Abstract available
    
    
    November 2024
23. 
    Author Response: Fine Particulate Matter and Parkinson Disease Risk Among Medicare Beneficiaries.
    Neurology. 2024;103:e210092.
    PubMed    
    
    
    
24. GUSOVSKY AV, Lin CC, Kerber K, Reynolds EL, et al
    Costs Are Still on the Rise for Commonly Prescribed Branded Neurologic Medications.
    Neurology. 2024;103:e210029.
    PubMed     Abstract available
    
    
    
25. AAMODT WW, Sun C, Dahodwala N, Elser H, et al
    End-of-Life Health Care Service Use and Cost Among Medicare Decedents With Neurodegenerative Diseases.
    Neurology. 2024;103:e209925.
    PubMed     Abstract available
    
    
    
26. 
    Association Between Orthostatic Hypotension and Dementia in Patients With Parkinson Disease and Multiple System Atrophy.
    Neurology. 2024;103:e209986.
    PubMed    
    
    
    October 2024
27. KIM HK, Biessels GJ, Yu MH, Hong N, et al
    SGLT2 Inhibitor Use and Risk of Dementia and Parkinson Disease Among Patients With Type 2 Diabetes.
    Neurology. 2024;103:e209805.
    PubMed     Abstract available
    
    
    
28. YOU M, Grobois L, Etienne M
    Reader Response: Fine Particulate Matter and Parkinson Disease Risk Among Medicare Beneficiaries.
    Neurology. 2024;103:e209374.
    PubMed    
    
    
    
29. BRENNER SR
    Reader Response: Fine Particulate Matter and Parkinson Disease Risk Among Medicare Beneficiaries.
    Neurology. 2024;103:e209911.
    PubMed    
    
    
    
30. KRZYZANOWSKI B
    Author Response: Fine Particulate Matter and Parkinson Disease Risk Among Medicare Beneficiaries.
    Neurology. 2024;103:e209334.
    PubMed    
    
    
    
31. LEWIS A, Galetta SL
    Editors' Note: Fine Particulate Matter and Parkinson Disease Risk Among Medicare Beneficiaries.
    Neurology. 2024;103:e209851.
    PubMed    
    
    
    
32. KRZYZANOWSKI B
    Author Response: Fine Particulate Matter and Parkinson Disease Risk Among Medicare Beneficiaries.
    Neurology. 2024;103:e209412.
    PubMed    
    
    
    September 2024
33. SCHULZ RS, Glatz T, Buring JE, Rist PM, et al
    Migraine and Risk of Parkinson Disease in Women: A Cohort Study.
    Neurology. 2024;103:e209747.
    PubMed     Abstract available
    
    
    
34. ANASTASSIADIS C, Martinez-Valbuena I, Vasilevskaya A, Thapa S, et al
    CSF alpha-Synuclein Seed Amplification Assay in Patients With Atypical Parkinsonian Disorders.
    Neurology. 2024;103:e209818.
    PubMed     Abstract available
    
    
    
35. GALLAGHER J, Gochanour C, Caspell-Garcia C, Dobkin RD, et al
    Long-Term Dementia Risk in Parkinson Disease.
    Neurology. 2024;103:e209699.
    PubMed     Abstract available
    
    
    August 2024
36. DAYAN E
    Neuropathologic Processes Linked to Brain Network Resilience in Parkinson Disease: Local or Distributed Effects?
    Neurology. 2024;103:e209731.
    PubMed    
    
    
    
37. FRIGERIO I, Broeders TAA, Lin CP, Bouwman MMA, et al
    Pathologic Substrates of Structural Brain Network Resilience and Topology in Parkinson Disease Decedents.
    Neurology. 2024;103:e209678.
    PubMed     Abstract available
    
    
    
38. DOMENIGHETTI C, Sugier PE, Ashok Kumar Sreelatha A, Schulte C, et al
    Association of Body Mass Index and Parkinson Disease: A Bidirectional Mendelian Randomization Study.
    Neurology. 2024;103:e209620.
    PubMed     Abstract available
    
    
    
39. YOU J, Wang L, Wang Y, Kang J, et al
    Prediction of Future Parkinson Disease Using Plasma Proteins Combined With Clinical-Demographic Measures.
    Neurology. 2024;103:e209531.
    PubMed     Abstract available
    
    
    
40. NISHIDA A, Shima A, Kambe D, Furukawa K, et al
    Frontoparietal-Striatal Network and Nucleus Basalis Modulation in Patients With Parkinson Disease and Gait Disturbance.
    Neurology. 2024;103:e209606.
    PubMed     Abstract available
    
    
    
41. PARNETTI L, Gaetani L
    Biomarker-Based Prediction of Parkinson Disease: Time for a Shift in Neurologists' Attitude Toward Neurodegenerative Diseases.
    Neurology. 2024;103:e209600.
    PubMed    
    
    
    
42. MERINO RUIZ MC, Mortari MR
    Neurotransmitters and Networks Interplay in Cognition and Gait Disturbances in Patients With Parkinson Disease: Beyond Lesion Localization.
    Neurology. 2024;103:e209704.
    PubMed    
    
    
    July 2024
43. YOUNG CB, Cholerton B, Smith AM, Shahid-Besanti M, et al
    The Parkinson's Disease Composite of Executive Functioning: A Measure for Detecting Cognitive Decline in Clinical Trials.
    Neurology. 2024;103:e209609.
    PubMed     Abstract available
    
    
    
44. OH Y, Kim JS, Lyoo CH, Park G, et al
    Spatiotemporal Progression Patterns of Dopamine Availability and Deep Gray Matter Volume in Parkinson Disease-Related Cognitive Impairment.
    Neurology. 2024;103:e209498.
    PubMed     Abstract available
    
    
    
45. HILKENS NA, Hammerton G, De Vries NM, Bloem BR, et al
    Guide to Decomposition of Causal Effects Into Mediation, Interaction, and Direct Effects: Case Study on Aerobic Exercise and Parkinson Disease.
    Neurology. 2024;103:e209547.
    PubMed     Abstract available
    
    
    June 2024
46. KIM S, Na HK, Sun Y, Yoon YJ, et al
    Regional Burden of Enlarged Perivascular Spaces and Cognition and Neuropsychiatric Symptoms in Drug-Naive Patients With Parkinson Disease.
    Neurology. 2024;102:e209483.
    PubMed     Abstract available
    
    
    
47. LE HERON C, Horne KL, MacAskill MR, Livingstone L, et al
    Cross-Sectional and Longitudinal Association of Clinical and Neurocognitive Factors With Apathy in Patients With Parkinson Disease.
    Neurology. 2024;102:e209301.
    PubMed     Abstract available
    
    
    
48. DI LUCA DG, Perlmutter JS
    Time for Clinical Dopamine Transporter Scans in Parkinsonism?: Not DAT Yet.
    Neurology. 2024;102:e209558.
    PubMed    
    
    
    
49. HOY CW, Chiong W
    The Ethical Landscape of Prodromal Parkinson Disease: Considerations for Shared Decision-Making and Health Equity.
    Neurology. 2024;102:e209522.
    PubMed    
    
    
    
50. HASTINGS A, Cullinane P, Wrigley S, Revesz T, et al
    Neuropathologic Validation and Diagnostic Accuracy of Presynaptic Dopaminergic Imaging in the Diagnosis of Parkinsonism.
    Neurology. 2024;102:e209453.
    PubMed     Abstract available
    
    
    
51. REES RN, Noyce AJ, Schrag AE
    Identification of Prodromal Parkinson Disease: We May Be Able to But Should We?
    Neurology. 2024;102:e209394.
    PubMed     Abstract available
    
    
    May 2024
52. RUS T, Cuderman A, Georgiev D
    Parkinsonism Associated With Traumatic Hemorrhage in Substantia Nigra: Role of Presynaptic Dopaminergic Imaging.
    Neurology. 2024;102:e209384.
    PubMed    
    
    
    
53. DOPPLER CEJ, Seger A, Farrher E, Regio Brambilla C, et al
    Glutamate Signaling in Patients With Parkinson Disease With REM Sleep Behavior Disorder.
    Neurology. 2024;102:e209271.
    PubMed     Abstract available
    
    
    April 2024
54. BROWN G, De Jesus S
    Bridging the Gap: Local Field Potentials Offer a Peek Into the Brain of a Person With Parkinson Disease.
    Neurology. 2024;102:e209283.
    PubMed     Abstract available
    
    
    
55. ZHAO Y, Lai Y, Konijnenberg H, Huerta JM, et al
    Association of Coffee Consumption and Prediagnostic Caffeine Metabolites With Incident Parkinson Disease in a Population-Based Cohort.
    Neurology. 2024;102:e209201.
    PubMed     Abstract available
    
    
    
56. ZHANG D, Zhou L, Lu C, Feng T, et al
    Free-Water Imaging of the Nucleus Basalis of Meynert in Patients With Idiopathic REM Sleep Behavior Disorder and Parkinson Disease.
    Neurology. 2024;102:e209220.
    PubMed     Abstract available
    
    
    
57. LAPADAT A, Nielsen SS, Racette B, Krzyzanowski B, et al
    Application of Simazine, Atrazine, and Lindane Pesticides Are Associated with Incident Parkinson's Disease Risk in the Rocky Mountain Region (S2.002).
    Neurology. 2024;102.
    PubMed     Abstract available
    
    
    
58. CAMPBELL M, Grossen S, Carr E, Eid A, et al
    Precision-mapping Functional Connectivity in Parkinson Disease: Feasibility & Reliability (P7-3.005).
    Neurology. 2024;102.
    PubMed     Abstract available
    
    
    
59. THOMAS E, Walker H, Middlebrooks E, McCullough B, et al
    Frameless, Virtual Cone Linac-based Stereotactic Radiosurgery for Essential & Parkinsonian Tremor: A Phase I/II Prospective Clinical Trial (S35.001).
    Neurology. 2024;102.
    PubMed     Abstract available
    
    
    March 2024
60. PARNETTI L, Paoletti FP
    Fluid Biomarkers for Trial Enrichment and Effect Monitoring in Disease-Modifying Treatments for Parkinson Disease.
    Neurology. 2024;102:e209194.
    PubMed    
    
    
    
61. HUTCHISON RM, Fraser K, Yang M, Fox T, et al
    Cinpanemab in Early Parkinson Disease: Evaluation of Biomarker Results From the Phase 2 SPARK Clinical Trial.
    Neurology. 2024;102:e209137.
    PubMed     Abstract available
    
    
    February 2024
62. TURNER RS
    Screening for Cognitive Decline in Isolated/Idiopathic REM Sleep Behavior Disorder: Which Test Is Best?
    Neurology. 2024;102:e208097.
    PubMed    
    
    
    
63. TOSIN MH, Goetz CG, Stebbins GT
    Patient With Parkinson Disease and Care Partner Perceptions of Key Domains Affecting Health-Related Quality of Life.
    Neurology. 2024;102:e208028.
    PubMed     Abstract available
    
    
    
64. COUSINS KAQ, Irwin DJ, Tropea TF, Rhodes E, et al
    Evaluation of ATN(PD) Framework and Biofluid Markers to Predict Cognitive Decline in Early Parkinson Disease.
    Neurology. 2024;102:e208033.
    PubMed     Abstract available
    
    
    
65. RAHAYEL S, Postuma R, Baril AA, Misic B, et al
    (99m)Tc-HMPAO SPECT Perfusion Signatures Associated With Clinical Progression in Patients With Isolated REM Sleep Behavior Disorder.
    Neurology. 2024;102:e208015.
    PubMed     Abstract available
    
    
    January 2024
66. KAHLON S, Barton CR, Abu Libdeh A, O'Malley JA, et al
    Emerging Subspecialties: Pediatric Movement Disorders Neurology.
    Neurology. 2024;102:e208050.
    PubMed     Abstract available
    
    
    December 2023
67. ELLIOTT JE, Bryant-Ekstrand MD, Keil AT, Ligman BR, et al
    Frequency of Orthostatic Hypotension in Isolated REM Sleep Behavior Disorder.
    Neurology. 2023;101:e2545-e2559.
    PubMed     Abstract available
    
    
    
68. ISHIKAWA K
    How Certain Are You When Making the Diagnosis of Multiple System Atrophy?
    Neurology. 2023;101:1081-1082.
    PubMed     Abstract available
    
    
    November 2023
69. PURNER D, Hormozi M, Weiss D, Barbe MT, et al
    Nationwide Retrospective Analysis of Combinations of Advanced Therapies in Patients With Parkinson Disease.
    Neurology. 2023 Nov 1:10.1212/WNL.0000000000207858.
    PubMed     Abstract available
    
    
    October 2023
70. KRZYZANOWSKI B, Nielsen SS, Turner JR, Racette BA, et al
    Fine Particulate Matter and Parkinson Disease Risk Among Medicare Beneficiaries.
    Neurology. 2023 Oct 30:10.1212/WNL.0000000000207871.
    PubMed     Abstract available
    
    
    
71. DARWEESH SK, Burke JF, Peters S
    Air Pollution and Parkinson Disease: Increasing Our Risk Each Breath We Take?
    Neurology. 2023 Oct 30:10.1212/WNL.0000000000207972.
    PubMed    
    
    
    
72. ROMANOWSKA J, Bjornevik K, Cortese M, Tuominen JA, et al
    Association Between Use of Any of the Drugs Prescribed in Norway and the Subsequent Risk of Parkinson Disease: A Drug-wide Association Study.
    Neurology. 2023 Oct 10:10.1212/WNL.0000000000207899.
    PubMed     Abstract available
    
    
    
73. BEAUCHAMP LC, Dore V, Villemagne VL, Xu S, et al
    Utilizing (18)F-AV-133 VMAT2 PET Imaging to Monitor Progressive Nigrostriatal Degeneration in Parkinson Disease.
    Neurology. 2023 Oct 10:10.1212/WNL.0000000000207748.
    PubMed     Abstract available
    
    
    August 2023
74. RAMATCHANDIRANE B, Rebello A, Syamala DD, Ganne P, et al
    Bilateral Iris Atrophy in a Patient With Parkinsonism.
    Neurology. 2023 Aug 30:10.1212/WNL.0000000000207743.
    PubMed    
    
    
    
75. KOSKA V, Albrecht P
    Inner Retinal Thickness Changes in Prevalent and Incident Parkinson Disease: A Potential Biomarker With Prognostic Value?
    Neurology. 2023 Aug 21:10.1212/WNL.0000000000207780.
    PubMed    
    
    
    
76. WAGNER SK, Romero-Bascones D, Cortina-Borja M, Williamson DJ, et al
    Retinal Optical Coherence Tomography Features Associated With Incident and Prevalent Parkinson Disease.
    Neurology. 2023 Aug 21:10.1212/WNL.0000000000207727.
    PubMed     Abstract available
    
    
    
77. ALTAMIMI R, Aldhalaan H, Tous E, Nicolas-Jilwan M, et al
    Teaching NeuroImages: The Putaminal Eye, A Highly Characteristic Imaging Feature of MEGDEL Syndrome.
    Neurology. 2023 Aug 21:10.1212/WNL.0000000000207823.
    PubMed    
    
    
    
78. PARNETTI L, Bellomo G
    Advances in Diagnosis and Prognosis of Parkinson Disease: Value of Cerebrospinal Fluid Proteomics.
    Neurology. 2023 Aug 16:10.1212/WNL.0000000000207724.
    PubMed    
    
    
    
79. TSUKITA K, Sakamaki-Tsukita H, Kaiser S, Zhang L, et al
    High-Throughput CSF Proteomics and Machine Learning to Identify Proteomic Signatures for Parkinson Disease Development and Progression.
    Neurology. 2023 Aug 16:10.1212/WNL.0000000000207725.
    PubMed     Abstract available
    
    
    
80. FRANKLIN GL
    A Letter From a Wise Man With Parkinson Disease.
    Neurology. 2023 Aug 1:10.1212/WNL.0000000000207660.
    PubMed    
    
    
    July 2023
81. CAMICIOLI RM, Colosimo C
    Neuropsychiatric Symptoms and Parkinson Disease: Are We Looking Carefully Enough?
    Neurology. 2023 Jul 31:10.1212/WNL.0000000000207722.
    PubMed    
    
    
    
82. LEE YG, Park M, Jeong SH, Baik K, et al
    Association of Neuropsychiatric Symptom Profiles With Cognitive Decline in Patients With Parkinson Disease and Mild Cognitive Impairment.
    Neurology. 2023 Jul 31:10.1212/WNL.0000000000207623.
    PubMed     Abstract available
    
    
    
83. BENARROCH E
    What Is the Role of the Intralaminar Thalamic Input to the Striatum and Its Potential Implications in Parkinson Disease?
    Neurology. 2023;101:118-123.
    PubMed    
    
    
    
84. AGRAWAL S, Leurgans SE, Nag S, Oveisgharan S, et al
    Effects of Cerebrovascular and Lewy Body Pathology on Parkinsonian Signs in Community-Dwelling Older Adults.
    Neurology. 2023 Jul 12:10.1212/WNL.0000000000207497.
    PubMed     Abstract available
    
    
    June 2023
85. 
    Cutaneous alpha-Synuclein Signatures in Patients With Multiple System Atrophy and Parkinson Disease.
    Neurology. 2023 Jun 30:10.1212/WNL.0000000000207614.
    PubMed    
    
    
    
86. NELSON PT, Jicha GA
    Surprising Synergy Between Cerebrovascular and Lewy Body Disease in Parkinsonism.
    Neurology. 2023 Jun 21:10.1212/WNL.0000000000207572.
    PubMed    
    
    
    
87. ZHANG Y, Zhang Y, Mao C, Jiang Z, et al
    Association of Cortical Gyrification With Imaging and Serum Biomarkers in Patients With Parkinson Disease.
    Neurology. 2023 Jun 2:10.1212/WNL.0000000000207410.
    PubMed     Abstract available
    
    
    May 2023
88. WANG L, Zhou C, Zhang W, Zhang M, et al
    Association of Cortical and Subcortical Microstructure with Clinical Progression and Fluid Biomarkers in Patients With Parkinson Disease.
    Neurology. 2023 May 18:10.1212/WNL.0000000000207408.
    PubMed     Abstract available
    
    
    
89. PORTUGAL B, Artaud F, Degaey I, Roze E, et al
    Association of Physical Activity and Parkinson Disease in Women: Long-term Follow-up of the E3N Cohort Study.
    Neurology. 2023 May 17:10.1212/WNL.0000000000207424.
    PubMed     Abstract available
    
    
    
90. CHAHINE LM, Darweesh SKL
    Physical Activity and the Risk of Parkinson Disease: Moving in the Right Direction.
    Neurology. 2023 May 17:10.1212/WNL.0000000000207527.
    PubMed    
    
    
    
91. IRANZO A, Mammana A, Munoz-Lopetegi A, Dellavalle S, et al
    Misfolded alpha-Synuclein Assessment in the Skin and CSF by RT-QuIC in Isolated REM Sleep Behavior Disorder.
    Neurology. 2023;100:e1944-e1954.
    PubMed     Abstract available
    
    
    April 2023
92. BRUMM MC, Pierz KA, Lafontant DE, Caspell-Garcia C, et al
    Updated Percentiles for the University of Pennsylvania Smell Identification Test in Adults 50 Years of Age and Older.
    Neurology. 2023;100:e1691-e1701.
    PubMed     Abstract available
    
    
    
93. PARNETTI L, Bellomo G
    On the Track of alpha-Synuclein in the Body: Skin Biopsies for Diagnosing Synucleinopathies?
    Neurology. 2023;100:691-692.
    PubMed    
    
    
    
94. DI LUCA DG, Luo S, Liu H, Cohn M, et al
    Racial and Ethnic Differences in Health-Related Quality of Life for Individuals with Parkinson Disease Across Centers of Excellence.
    Neurology. 2023 Apr 5:10.1212/WNL.0000000000207247.
    PubMed     Abstract available
    
    
    February 2023
95. REYNOLDS EL, Gallagher G, Hill CE, Banerjee M, et al
    Costs and Utilization of New-to-Market Neurologic Medications.
    Neurology. 2023;100:e884-e898.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Parkinson's Disease is free of charge.